View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Oct. 26, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	ZIOP
Entity Registrant Name	ZIOPHARM ONCOLOGY INC
Entity Central Index Key	0001107421
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		130,888,901

BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 163,843	$ 42,803
Receivables	369	145
Prepaid expenses and other current assets	8,268	1,139
Total current assets	172,480	44,087
Property and equipment, net	262	531
Deposits	128	128
Other non-current assets	491	491
Total assets	173,361	45,237
Current liabilities:
Accounts payable	4,154	2,004
Accrued expenses	18,138	7,182
Deferred rent - current portion	402	280
Deferred revenue - current portion	6,933	1,360
Total current liabilities	29,627	10,826
Deferred rent	379	570
Deferred revenue	49,514
Total liabilities	79,520	11,396
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value; 30,000,000 shares authorized and no shares issued and outstanding
Common stock, $0.001 par value; 250,000,000 shares authorized; 130,887,901 and 104,452,105 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	131	104
Additional paid-in capital - common stock	576,934	406,349
Accumulated deficit	(483,224)	(372,612)
Total stockholders' equity	93,841	33,841
Total liabilities and stockholders' equity	$ 173,361	$ 45,237

BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	30,000,000	30,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	130,887,901	104,452,105
Common stock, shares outstanding	130,887,901	104,452,105

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Research contract revenue	$ 1,869	$ 633	$ 2,413	$ 1,033
Operating expenses:
Research and development, including costs of research contracts	16,970	9,733	98,643	24,621
General and administrative	3,065	2,842	14,388	9,315
Total operating expenses	20,035	12,575	113,031	33,936
Loss from operations	(18,166)	(11,942)	(110,618)	(32,903)
Other income (expense), net	(4)	2	6	(6)
Change in fair value of warrants		5,847		11,529
Net loss	$ (18,170)	$ (6,093)	$ (110,612)	$ (21,380)
Net loss per share - basic and diluted	$ (0.14)	$ (0.06)	$ (0.89)	$ (0.21)
Weighted average common shares outstanding used to compute net loss per share - basic and diluted	129,732,356	100,428,520	123,911,796	100,360,825

STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2015 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital Common Stock	Accumulated Deficit
Balance (in shares) at Dec. 31, 2014		104,452,105
Balance at Dec. 31, 2014	$ 33,841	$ 104	$ 406,349	$ (372,612)
Stock-based compensation	$ 6,054		6,054
Exercise of employee stock options (in shares)	2,938,161	2,208,268
Exercise of employee stock options	$ 3,366	$ 2	3,364
Restricted stock awards (in shares)		1,054,186
Restricted stock awards		$ 1	(1)
Repurchase of common stock (Shares)		(3,711)
Repurchase of common stock	(34)		(34)
Repurchase of restricted common stock and stock option (in shares)		(45,110)
Repurchase of restricted common stock and stock option	(379)		(379)
Issuance of common stock in public offering (in shares)		11,500,000
Issuance of common stock in public offering	94,320	$ 12	94,308
Issuance of common stock in licensing agreement (in shares)		11,722,163
Issuance of common stock in licensing agreement	67,285	$ 12	67,273
Net loss	(110,612)			(110,612)
Balance (in shares) at Sep. 30, 2015		130,887,901
Balance at Sep. 30, 2015	$ 93,841	$ 131	$ 576,934	$ (483,224)

STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2015 USD ($)
Issuance of common stock in public offering, issuance expenses	$ 267

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (110,612)	$ (21,380)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	295	339
Stock-based compensation	6,054	3,583
Change in fair value of warrants		(11,529)
Common stock issued in exchange for license agreement	67,285
Loss on disposal of fixed assets	(1)
(Increase) decrease in:
Receivables	(224)	(63)
Prepaid expenses and other current assets	(7,129)	464
Other noncurrent assets		15
Increase (decrease) in:
Accounts payable	2,150	1,531
Accrued expenses	10,956	1,447
Deferred revenue	55,087	(1,033)
Deferred rent	(69)	(154)
Net cash provided by (used in) operating activities	23,792	(26,780)
Cash flows from investing activities:
Purchases of property and equipment	(25)	(193)
Net cash used in investing activities	(25)	(193)
Cash flows from financing activities:
Proceeds from exercise of stock options	3,366	1,323
Repurchase of restricted common stock	(379)	(132)
Repurchase of common stock	(34)
Proceeds from the issuance of common stock, net	94,320
Proceeds from exercise of warrants		3,700
Net cash provided by financing activities	97,273	4,891
Net increase (decrease) in cash and cash equivalents	121,040	(22,082)
Cash and cash equivalents, beginning of period	42,803	68,204
Cash and cash equivalents, end of period	163,843	46,122
Supplementary disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplementary disclosure of noncash investing and financing activities:
Exercise of equity-classified warrants to common shares		$ 692
Issuance of common stock in license agreement	$ 67,285

Business

9 Months Ended

Sep. 30, 2015

Business

1. Business

Overview

ZIOPHARM Oncology, Inc., which is referred to herein as “ZIOPHARM” or the “Company,” is a biopharmaceutical company that seeks to acquire, develop and commercialize, on its own or with partners, a diverse portfolio of cancer therapies and for graft-vs-host disease to address unmet medical needs.

The Company’s operations to date have consisted primarily of raising capital and conducting research and development. The Company’s fiscal year ends on December 31.

The Company has operated at a loss since its inception in 2003 and has minimal revenues. The Company anticipates that its losses will continue for the foreseeable future. At September 30, 2015, the Company’s accumulated deficit was approximately $483.2 million. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, intellectual property developments, regulatory changes or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be obtained by the Company, or if obtained, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations.

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States have been condensed or omitted pursuant to such rules and regulations.

It is management’s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2014, included in the Company’s Annual Report on Form 10-K filed with the SEC on February 26, 2015, or the Form 10-K.

The year-end balance sheet data was derived from the audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States.

The results disclosed in the statements of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full fiscal year.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.

The Company’s most significant estimates and judgments used in the preparation of its financial statements are:

•

Clinical trial expenses;

•

Fair value measurements for stock-based compensation; and

•

Income taxes.

Subsequent Events

The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. During this period, the Company did not have any material subsequent events that impacted its financial statements or disclosures.

Financings

9 Months Ended

Sep. 30, 2015

Financings

2. Financings

On February 3, 2015, the Company entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the several underwriters named therein, relating to the issuance and sale of 10,000,000 shares of its common stock. The price to the public in the offering was $8.75 per share, and the underwriters agreed to purchase the shares from the Company pursuant to the underwriting agreement at a purchase price of $8.225 per share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,500,000 shares of common stock at a purchase price of $8.225 per share. The offering was made pursuant to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-201826) previously filed with the SEC, and a prospectus supplement thereunder. The underwriters purchased the 10,000,000 shares and the additional 1,500,000 shares on February 9 and February 17, 2015, respectively. The net proceeds from the offering were approximately $94.3 million after deducting underwriting discounts and estimated offering expenses payable by the Company.

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2015
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies The Company’s significant accounting policies were identified in the Company’s Form 10-K for the fiscal year ended December 31, 2014. There have been no material changes in those policies since the filing of its Form 10-K.

Fair Value Measurements

9 Months Ended

Sep. 30, 2015

Fair Value Measurements

4. Fair Value Measurements

The Company accounts for its financial assets and liabilities using fair value measurements. The accounting standard defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows:

•

Level 1 - Quoted prices in active markets for identical assets or liabilities.

•

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Assets and liabilities measured at fair value on a recurring basis as of September 30, 2015 and December 31, 2014 were as follows:


($ in thousands)			Fair Value Measurements at Reporting Date Using
Description	Balance as of September 30, 2015		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	160,930	$	160,930	$	—	$	—


($ in thousands)			Fair Value Measurements at Reporting Date Using
Description	Balance as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	37,290	$	37,290	$	—	$	—

The cash equivalents represent deposits in a short term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.

Net Loss per Share

9 Months Ended

Sep. 30, 2015

Net Loss per Share

5. Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company’s potential dilutive shares, which include outstanding common stock options, unvested restricted stock and warrants, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potential shares of common stock at September 30, 2015 and 2014 consisted of the following:


	September 30,
	2015		2014
Stock options		3,655,135		5,792,428
Unvested restricted common stock		1,127,703		283,433
Warrants		—		8,235,076

		4,782,838		14,310,937

Commitments and Contingencies

9 Months Ended

Sep. 30, 2015

Commitments and Contingencies

6. Commitments and Contingencies

Operating Leases

Prior to December 31, 2012, the Company entered into an operating lease in New York, NY, consisting of 6,251 square feet of office space. In accordance with this agreement, the Company entered into a letter of credit in the amount of $388 thousand, naming the Company’s landlord as beneficiary. In January 2012, the Company amended the lease agreement, adding 1,008 square feet of office space. As of December 31, 2012, the Company occupied 7,259 square feet of space in New York, NY, and maintained a $388 thousand letter of credit. The collateral for the letter of credit is restricted cash and recorded in other non-current assets on the balance sheet as of September 30, 2015. The lease for office space in New York, NY expires in October 2018.

On October 17, 2013, the Company entered into a sublease agreement to lease all of its New York office space to a subtenant. The Company remains primarily liable to pay rent on the original lease. The Company recorded a loss on the sublease in the amount of $729 thousand for the year ended December 31, 2013, representing the remaining contractual obligation of $2.3 million, less $1.6 million in payments from its subtenant. The Company retired assets as a result of this sublease with a net book value of $392 thousand, and recorded a loss on disposal of fixed assets for the same amount for the year ended December 31, 2013. The Company continues to maintain the $388 thousand letter of credit in respect of the New York office space.

Prior to December 31, 2012, the Company entered into separate operating lease agreements for various spaces in a building in Boston, MA. That space consisted of 5,249 square feet on the first floor, 8,538 square feet on the second floor, and 6,959 square feet on the third floor. In June 2012, the Company re-negotiated a master lease for the entire Boston office space, whereby it added 9,800 square feet of office space on the fourth floor, surrendered 4,113 square feet from the second floor, and incorporated all three lease agreements under the same master agreement expiring in August 2016. The Company provided an additional $41 thousand security deposit for the additional space on the fourth floor. As of September 30, 2015, a total security deposit of $127 thousand is included in deposits on the balance sheet.

On August 30, 2013, the Company entered into a sublease agreement to lease 5,249 square feet in its Boston office to a subtenant. The Company remains liable to pay rent on the original lease. The Company recorded a loss on the sublease in the amount of $42 thousand for the year ended December 31, 2013, representing the remaining contractual obligation of $367 thousand, less $325 thousand in payments from its subtenant. This sublease tenant vacated the leased premises in October 2014. At December 31, 2014, the Company applied the $20 thousand deposit received from the sublease tenant against its outstanding rent obligation. On March 31, 2015, the Company recorded a loss of $167 thousand on the first floor sublease. On May 22, 2015, the Company subleased the vacant office space for approximately $105 thousand for the period of June 2015 through August 2016, and the tenant provided a security deposit of $17 thousand. Since the prior lease obligation has been fully expensed, rent received from the tenant will reduce current rent expense. At September 30, 2015, the Company occupies 21,184 square feet of space in its Boston, MA office.

Total rent expense was approximately $581 thousand and $445 thousand for the nine months ended September 30, 2015 and 2014, respectively.

The Company records rent expense on a straight-line basis over the term of the lease. Accordingly, the Company has recorded a liability for deferred rent at September 30, 2015 and December 31, 2014 of $781 thousand ($402 thousand current and $379 thousand long-term) and $850 thousand ($280 thousand current and $570 thousand long-term), respectively, which is recorded in deferred rent on the balance sheet.

License Agreements

Exclusive Channel Partner Agreement with Intrexon Corporation for the Cancer Programs

On January 6, 2011, the Company entered into an Exclusive Channel Partner Agreement, or the Channel Agreement, with Intrexon Corporation, or Intrexon, that governs a “channel partnering” arrangement in which the Company uses Intrexon’s technology directed towards in vivo expression of effectors in connection with the development of Ad-RTS-IL-12 + veledimex and DC-RTS-IL-12 + veledimex and generally to research, develop and commercialize products, in each case in which DNA is administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which the Company collectively refers to as the Cancer Program. This Channel Agreement establishes committees comprised of representatives of the Company and Intrexon that govern activities related to the Cancer Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property.

The Channel Agreement grants the Company a worldwide license to use patents and other intellectual property of Intrexon in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving DNA administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which is collectively referred to as the ZIOPHARM Products. Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of ZIOPHARM Products, and otherwise is non-exclusive. Subject to limited exceptions, the Company may not sublicense these rights without Intrexon’s written consent.

Under the Channel Agreement, and subject to certain exceptions, the Company is responsible for, among other things, the performance of the Cancer Program, including the development, commercialization and certain aspects of manufacturing of ZIOPHARM Products. Intrexon is responsible for establishing manufacturing capabilities and facilities for the bulk manufacture of products developed under the Cancer Program, certain other aspects of manufacturing and costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and maintenance of Intrexon’s patents.

Subject to certain expense allocations and other offsets provided in the Channel Agreement, the Company will pay Intrexon on a quarterly basis 50% of net profits derived in that quarter from the sale of ZIOPHARM Products, calculated on a ZIOPHARM Product-by- ZIOPHARM Product basis. The Company has likewise agreed to pay Intrexon on a quarterly basis 50% of revenue obtained in that quarter from a sublicensor in the event of a sublicensing arrangement. In addition, in partial consideration for each party’s execution and delivery of the Channel Agreement, the Company entered into a stock purchase agreement with Intrexon.

Upon termination of the Channel Agreement, the Company may continue to develop and commercialize any ZIOPHARM Product that, at the time of termination:

•

Is being commercialized by the Company;

•

Has received regulatory approval;

•

Is a subject of an application for regulatory approval that is pending before the applicable regulatory authority; or

•

Is the subject of at least an ongoing Phase 2 clinical trial (in the case of a termination by Intrexon due to an uncured breach or a voluntary termination by the Company), or an ongoing Phase 1 clinical trial in the field (in the case of a termination by the Company due to an uncured breach or a termination by Intrexon following an unconsented assignment by the Company or its election not to pursue development of a Superior Therapy (as defined in the Channel Agreement)).

The Company’s obligation to pay 50% of net profits or revenue described above with respect to these “retained” products will survive termination of the Channel Agreement.

On March 27, 2015, the Company and Intrexon entered into an Exclusive Channel Partner Amendment, or ECP Amendment, amending the Channel Agreement. The ECP Amendment modifies the scope of the parties’ collaboration under the Channel Agreement in connection with the Ares Trading Agreement discussed below. Pursuant to the ECP Amendment, the chimeric antigen receptor T-Cell products to be developed and commercialized pursuant to the Ares Trading Agreement shall be included within the Intrexon/ZIOPHARM collaboration under the Channel Agreement. The ECP Amendment provides that Intrexon will pay to the Company fifty percent of all payments Intrexon receives for upfronts, milestones and royalties under the Ares Trading Agreement.

Exclusive Channel Collaboration Agreement with Intrexon Corporation for Graft-Versus-Host Disease (GvHD)

On September 28, 2015, the Company, entered into a new Exclusive Channel Collaboration Agreement, or the GvHD Agreement, with Intrexon Corporation, or Intrexon, whereby the Company will use Intrexon’s technology directed towards in vivo expression of effectors to research, develop and commercialize products for use in the treatment or prevention of graft-versus-host disease, or GvHD. The exclusive collaboration, or the GvHD Program, will focus on the pursuit of the following engineered cell therapy strategies, used either separately or in combination, for the targeted treatment of GvHD: (i) the infusion of regulatory T-cells expressing membrane-bound and/or soluble interleukin-2 and (ii) the deployment of orally delivered, genetically modified L. lactis that express interleukin-2 to modulate immune function. The GvHD Agreement establishes committees comprised of Company and Intrexon representatives that will govern activities related to the GvHD Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization activities and intellectual property.

The GvHD Agreement grants the Company a worldwide license to use specified patents and other intellectual property of Intrexon in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products developed under the GvHD Program, or the Products. Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of the Products, and otherwise is non-exclusive. Subject to limited exceptions, the Company may not sublicense the rights described without Intrexon’s written consent.

Under the GvHD Agreement, and subject to certain exceptions, the Company is responsible for, among other things, the performance of the GvHD Program including development, commercialization and certain aspects of manufacturing of the Products. Among other things, Intrexon is responsible for the costs of establishing manufacturing capabilities and facilities for the bulk manufacture of the Products, certain other aspects of manufacturing, costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and maintenance of Intrexon’s patents.

The Company will pay Intrexon a technology access fee of $10 million in cash and will reimburse Intrexon for all research and development costs. Subject to certain expense allocations and other offsets provided in the GvHD Agreement, the GvHDAgreement also provides for equal sharing of the profits derived from the sale of the Products.

During the first 24 months after September 28, 2015, the GvHD Agreement may be terminated by (i) either party in the event of a material breach by the other, except for the failure of the other party to use diligent efforts or to comply with any diligence obligations set forth in the GvHD Agreement and (ii) Intrexon under certain circumstances if the Company assigns its rights under the GvHD Agreement without Intrexon’s consent. Following such twenty-four month period, Intrexon may also terminate the GvHD Agreement if the Company elects not to pursue the development of the GvHD Program identified by Intrexon that is a “Superior Therapy,” as such term is defined in the GvHD Agreement. Also following such period, the Company may voluntarily terminate the GvHD Agreement upon 90 days’ written notice to Intrexon.

Upon termination of the GvHD Agreement, the Company may continue to develop and commercialize any Product that, at the time of termination:

•

is being commercialized by the Company,

•

has received regulatory approval,

•

is a subject of an application for regulatory approval that is pending before the applicable regulatory authority, or

•

is the subject of at least an ongoing Phase 2 clinical trial (in the case of a termination by Intrexon due to a Company uncured breach or a voluntary termination by the Company), or an ongoing Phase 1 clinical trial (in the case of a termination by the Company due to an Intrexon uncured breach or a termination by Intrexon following an unconsented assignment by the Company or the Company’s election not to pursue development of a Superior Therapy).

The Company’s obligation to pay 50% of net profits or revenue with respect to these “retained” products will survive termination of the GvHD Agreement.

The Company has determined that the rights acquired in the GvHD Agreement represent in-process research and development with no alternative future use. Accordingly, the Company recorded a charge of $10.0 million to research and development expense and included the obligation in current liabilities at September 30, 2015. The liability was subsequently paid in October 2015.

License Agreement—The University of Texas MD Anderson Cancer Center

On January 13, 2015, the Company, together with Intrexon, entered into a License Agreement, or the MD Anderson License, with The University of Texas MD Anderson Cancer Center, or MD Anderson. Pursuant to the MD Anderson License, the Company and Intrexon hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells and T cell receptors, or TCR’s arising from the laboratory of Laurence Cooper, M.D., Ph.D., who became the Chief Executive Officer of the Company on May 7, 2015 and was formerly a professor of pediatrics at MD Anderson and now currently a visiting scientist under that institution’s policies, as well as either co-exclusive or non-exclusive licenses under certain related technologies.

Pursuant to the terms of the MD Anderson License, MD Anderson received consideration consisting of $50 million in shares of the Company’s common stock (or 10,124,561 shares), and $50 million in shares of Intrexon’s common stock, in each case based on a trailing 20 day volume weighted average of the closing price of the Company’s and Intrexon’s common stock ending on the date prior to the announcement of the entry into the MD Anderson License, collectively referred to as the License Shares, pursuant to the terms of the License Shares Securities Issuance Agreement described below. The License Shares were issued to MD Anderson on March 11, 2015 pursuant to the terms of the MD Anderson License.

On January 9, 2015, in order to induce MD Anderson to enter into the MD Anderson License on an accelerated schedule, the Company and Intrexon entered into a letter agreement, or the Letter Agreement, pursuant to which MD Anderson received consideration of $7.5 million in shares of the Company’s common stock (or 1,597,602 shares), and $7.5 million in shares of Intrexon’s common stock, in each case based on a trailing 20 day volume weighted average of the closing price of the Company’s and Intrexon’s common stock ending on the date prior to the execution of the Letter Agreement, collectively referred to as the Incentive Shares, in the event that the MD Anderson License was entered into on or prior to 8:00 am Pacific Time on January 14, 2015. The Incentive Shares were issued to MD Anderson on March 11, 2015 pursuant to the terms of the Incentive Shares Securities Issuance Agreement described below.

On August 17, 2015, the Company, Intrexon and MD Anderson entered into a research and development agreement, or the Research and Development Agreement, to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs.

Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15 million and no greater than $20 million per year. The Company made two quarterly payments totaling an aggregate of $7.5 million under this arrangement. As of September 30, 2015, MD Anderson has used $372 thousand to offset costs incurred pursuant to the MD Anderson License and the Research and Development Agreement. The net balance of $7.1 million is included in other current assets at September 30, 2015. The Company made its third quarterly payment of $3.8 million on October 13, 2015.

The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the License; provided, however, that following the expiration of the term of the MD Anderson License, the Company and Intrexon shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Intrexon are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third party contract if the Company and Intrexon are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Intrexon, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Intrexon and may be terminated by the mutual written agreement of the Company, Intrexon and MD Anderson.

In connection with the License and the issuance of the License Shares and the Incentive Shares, on January 13, 2015, the Company and MD Anderson entered into a Registration Rights Agreement, or the Registration Rights Agreement, pursuant to which the Company agreed to file a “resale” registration statement, or the Registration Statement, registering the resale of the License Shares, the Incentive Shares and any other shares of the Company’s common stock held by MD Anderson on the date that the Registration Statement is filed Under the Registration Rights Agreement, the Company is obligated to maintain the effectiveness of the Registration Statement until all securities therein are sold or are otherwise can be sold pursuant to Rule 144, without any restrictions. A prospectus supplement under the Company’s already effective registration statement on Form S-3 (File No. 333-201826), was filed on April 1, 2015 in satisfaction of the Company’s obligations under the Registration Rights Agreement.

The Company has determined that the rights acquired in the MD Anderson License represent in process research and development with no alternative future use. Accordingly, the Company recorded a charge of $67.3 million to research and development expense representing the fair value of the 11,722,163 shares of its common stock on the date the MD Anderson License was executed.

Merck License and Collaboration Agreement

On March 27, 2015, the Company and Intrexon signed a worldwide License and Collaboration Agreement (“Merck Agreement”) with Ares Trading S.A. (“Ares Trading”), a subsidiary of the biopharmaceutical business of Merck KGaA, through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans.

Under the collaboration, Ares Trading will elect CAR-T targets, of which two have been selected, and for which Ares Trading will provide certain research funding. The Company is responsible for certain research and development expenditures. Once these candidates reach investigational new drug (IND) stage, the programs will be transferred to Ares Trading for clinical development and commercialization. The Company and Intrexon will also independently conduct research and development on other CAR-T candidates, with Ares Trading having the opportunity during clinical development to opt-in. The Company expects to perform multiple preclinical development programs, each consisting of the development of one product candidate, pursuant to the agreement.

Intrexon is entitled to receive $5.0 million payable in equal quarterly installments over two years for each identified product candidate, which will be used to fund discovery work. The Company will be responsible for costs exceeding the quarterly installments and all other costs of the preclinical research and development.

Ares Trading paid a non-refundable upfront fee of $115.0 million to Intrexon as consideration for entry into the Merck Agreement. Pursuant to the ECP Amendment, the Company is entitled to receive 50% of the upfront fee, or $57.5 million, which was received from Intrexon in July 2015.

The Merck Agreement provides for up to $413.0 million of potential payments for certain development and commercial milestones for each product candidate, and royalties ranging from the lower-single digits to the low-teens of net sales derived from the sale of products developed under agreement. The Merck Agreement also provides for up to $50.0 million of payments upon the achievement of certain technical milestones. Intrexon will pay 50% of all milestone and royalty payments that it receives under the Merck Agreement to the Company pursuant to the ECP Amendment.

The term of the Merck Agreement commenced in May 2015 and may be terminated by either party in the event of a material breach as defined in the agreement and may be terminated voluntarily by Ares Trading upon 90 days written notice to the Company.

The Company considered FASB Accounting Standards Codification 605-25, Multiple-Element Arrangements, in evaluating the appropriate accounting for the Merck Agreement. In accordance with this guidance, the Company identified the license and research and development services as the Company’s deliverables in the arrangement. The Company concluded that the license does not have standalone value from the research and development services. Accordingly, the Merck Agreement is accounted for by the Company as a single unit of accounting. The $57.5 million upfront payment received by the Company was recorded as deferred revenue and is being recognized over the estimated period of performance of the research and development services, beginning with the commencement of the research and development services. During the three and nine months ended September 30, 2015, the Company recognized $1.6 million of revenue related to the Merck Agreement. The remaining balance of deferred revenue associated with the upfront payment was $55.9 million, of which $6.4 million is current and $49.5 million is classified as long term at September 30, 2015.

License Agreement with DEKK-Tec, Inc.

On October 15, 2004, the Company entered into a license agreement with DEKK-Tec, Inc., or DEKK-Tec, pursuant to which it was granted an exclusive, worldwide license for palifosfamide.

In consideration for the license rights, DEKK-Tec is entitled to receive payments upon achieving certain milestones in varying amounts which on a cumulative basis may total $4.0 million. Of the aggregate milestone payments, most will be creditable against future royalty payments as referenced below. Additionally, the Company issued DEKK-Tec an option to purchase 27,616 shares of the Company’s common stock for $0.02 per share, of which 13,808 options are still outstanding. DEKK-Tec is entitled to receive single digit percentage royalty payments on the sales of palifosfamide should it be approved for commercial sale. The Company’s obligation to pay royalties will terminate on a country-by-country basis upon the expiration of all valid claims of patents in such country covering licensed product, subject to earlier termination in the event of defaults by the parties under the license agreement. No milestones under the license agreement have been reached or expensed since 2010.

License Agreement with Southern Research Institute

On December 22, 2004, the Company entered into an Option Agreement with the Southern Research Institute, or SRI, pursuant to which the Company was granted an exclusive option to obtain an exclusive license to SRI’s interest in certain intellectual property, including exclusive rights related to certain isophosphoramide mustard analogs. On February 5, 2007, the Company exercised its option and entered into an exclusive license agreement. Under the license agreement, the Company is required to remit minimum annual royalty payments of $25 thousand until the first commercial sale of a licensed product. These payments were made for the years ended December 31, 2014, 2013, and 2012. The Company may be required to make payments upon achievement of certain milestones in varying amounts which on a cumulative basis could total up to $775 thousand. In addition, SRI will be entitled to receive single digit percentage royalty payments on the sales of a licensed product in any country until all licensed patents rights in that country which are utilized in the product have expired. No milestones under the license agreement have been reached or expensed since the agreement’s inception.

Patent and Technology License Agreement—The University of Texas MD Anderson Cancer Center and the Texas A&M University System.

On August 24, 2004, the Company entered into a patent and technology license agreement with The Board of Regents of the University of Texas System, acting on behalf of The University of Texas MD Anderson Cancer Center and the Texas A&M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.

The Company issued options to purchase 50,222 shares outside of the Company’s stock option plans following the successful completion of certain clinical milestones, of which 37,666 have vested. The remaining 12,556 shares will vest upon enrollment of the first patient in a multi-center pivotal clinical trial i.e. a human clinical trial intended to provide the substantial evidence of efficacy necessary to support the filing of an approvable New Drug Application, or NDA. In addition, the Licensors are entitled to receive certain milestone payments. The Company may be required to make additional payments upon achievement of certain other milestones in varying amounts which on a cumulative basis could total up to an additional $4.5 million. In addition, the Licensors are entitled to receive single digit percentage royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances.

Collaboration Agreement with Solasia Pharma K.K.

On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K.K., or Solasia. Pursuant to the License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both IV and oral forms and related organic arsenic molecules, in all indications for human use in a pan- Asian/Pacific territory comprised of Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand.

As consideration for the license, the Company received an upfront payment of $5.0 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific territory, and will be entitled to receive additional payments of up to $32.5 million in development-based milestones and up to $53.5 million in sales-based milestones. The Company will also be entitled to receive double digit royalty payments from Solasia based upon net sales of licensed products in the applicable territories, once commercialized, and a percentage of sublicense revenues generated by Solasia. Under the License and Collaboration Agreement, the Company provided Solasia with drug product to conduct clinical trials. These transfers were accounted for as a reduction of research and development costs and an increase in collaboration receivables. The agreement provides that Solasia will be responsible for the development and commercialization of darinaparsin in the pan-Asian/Pacific territory.

On July 31, 2014, the Company entered into an amendment and restatement of the License and Collaboration Agreement granting Solasia an exclusive worldwide license to develop and commercialize darinaparsin, and related organoarsenic molecules, in both intravenous and oral forms in all indications for human use. In exchange, the Company will be eligible to receive from Solasia development-and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenues generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company’s Licensors will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Company’s license agreement with the Licensors.

The $5.0 million upfront payment received in March 2011 is being amortized over the period of the Company’s research and development effort. The Company originally estimated this period to be 75 months. In accordance with the amended and restated License and Collaboration Agreement with Solasia, the Company is no longer obligated to continue their research and development efforts in connection with the upfront payment. However, there are certain deliverables that are included in the amended and restated License and Collaboration Agreement including transfer of intellectual property and prior research and development results, which were originally estimated by management to be completed by March 31, 2015 when the amended and restated License and Collaboration Agreement was signed in July 2014. Management subsequently reassessed the period of performance related to the remaining transitional services to be completed under the amended and restated License and Collaboration Agreement and determined that the services are now expected to be completed by March 31, 2016. Accordingly, the Company has recorded $272 thousand and $816 thousand in revenue during the three and nine months ended September 30, 2015 respectively, and $633 thousand and $1.0 million in revenue during the three and nine months ended September 30, 2014. The remaining deferred revenue balance of $544 thousand at September 30, 2015 has been classified as current.

License Agreement with Baxter Healthcare Corporation

On November 3, 2006, the Company entered into a definitive Asset Purchase Agreement for indibulin and a License Agreement to proprietary nanosuspension technology with affiliates of Baxter Healthcare S.A. The purchase included the entire indibulin intellectual property portfolio as well as existing drug substance and capsule inventories. During 2014, we determined to no longer pursue clinical development of indibulin. During the years ended December 31, 2014 and 2013, the installment payments of $250 thousand were met and expensed. No payments have been made during the nine months ended September 30, 2015.

CRO Services Agreement with Novella Clinical, Inc.

On December 4, 2008, the Company entered into a Master Clinical Research Organization Services Agreement with Novella Clinical, Inc., or Novella, under which Novella provides clinical research organization, or CRO, services in support of the Company’s clinical trials. The work order for the newest trial being conducted by Novella was signed on November 2, 2012. Novella was entitled to cumulative payments of up to $790 thousand under these arrangements, which is payable in varying amounts upon Novella achieving specified milestones.

On August 18, 2014 and November 6, 2014, the Company signed two respective amendments of the Master Clinical Research Organization Services Agreement with Novella. The amendments reflect the removal of data management, statistical and clinical study report services, as well as a change in the timeline and scope of clinical trial support. During the year ended December 31, 2014, three clinical milestones were met and expensed totaling $236 thousand. The remaining milestone of $10 thousand was met and expensed during the quarter ended March 31, 2015. There are no remaining obligations under this agreement.

Related Party Transactions

9 Months Ended

Sep. 30, 2015

Related Party Transactions

7. Related Party Transactions

On January 6, 2011, the Company entered into an Exclusive Channel Partner Agreement, or Channel Agreement, which is referred to as the Channel Agreement, with Intrexon (Note 6). The Company’s director, Randall J. Kirk, is the CEO, a director, and the largest stockholder of Intrexon.

On March 27, 2015, the Company and Intrexon entered into a Second Amendment to Exclusive Channel Partner Agreement amending the Channel Agreement, which is referred to as the ECP Amendment. The ECP Amendment modified the scope of the parties’ collaboration under the Channel Agreement in connection with the worldwide License and Collaboration Agreement, or the Ares Trading Agreement, which the Company and Intrexon entered into with Ares Trading S.A., or Ares Trading, on March 27, 2015. The ECP Amendment provided that Intrexon will pay to the Company fifty percent of all payments that Intrexon receives for upfronts, milestones and royalties under the Ares Trading Agreement (Note 6). The Amendment also reduces Intrexon’s aggregate commitment under a Stock Purchase Agreement that the parties executed in connection with the initial Channel Agreement to purchase the Company’s common stock from $50.0 million to $43.5 million, which has been satisfied.

On January 13, 2015, the Company, together with Intrexon, entered into a license agreement with MD Anderson, which is referred to as the MD Anderson License. Pursuant to the MD Anderson License, the Company and Intrexon hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR-T cell therapies arising from the laboratory of Laurence Cooper, M.D., Ph.D., the Chief Executive Officer of the Company, formerly a professor of pediatrics at MD Anderson and now currently a visiting scientist under that institution’s policies, as well as either co-exclusive or non-exclusive licenses under certain related technologies. In partial consideration for entering into the MD Anderson License, the Company issued MD Anderson an aggregate of 11,722,163 shares of common stock for which the Company incurred $67.3 million charge. The Company has determined that the rights acquired in the MD Anderson License represent in-process research and development with no alternative future use. As a result of the common stock issued to MD Anderson in connection with these transactions, MD Anderson became a beneficial holder of more than five percent of the Company’s common stock. (Note 6).

On February 2, 2015, Intrexon purchased 1,440,000 shares of common stock in the Company’s public offering (Note 2) upon the same terms as others that participated in the offering.

On June 29, 2015, the Company purchased 3,711 shares of common stock from Intrexon, at a discount of 5% to the closing price of the Company’s common stock on the date of purchase, which represented fractional shares that resulted from Intrexon’s special stock dividend of the Company’s shares to Intrexon’s shareholders, for $34 thousand.

During the nine months ended September 30, 2015, the Company expensed $11.7 million for services performed by Intrexon, of which $5.7 million is included within current liabilities. During the nine months ended September 30, 2014, the Company expensed $9.1 million for services performed by Intrexon, of which $2.3 million was recorded within current liabilities.

On September 28, 2015, ZIOPHARM Oncology, Inc., or the Company, entered into an Exclusive Channel Collaboration Agreement, or the GvHD Agreement, with Intrexon Corporation, or Intrexon, whereby the Company will use Intrexon’s technology directed towards in vivo expression of effectors to research, develop and commercialize products for use in the treatment or prevention of graft-versus-host disease, or GvHD (Note 6).

The Company will pay Intrexon a technology access fee of $10 million in cash and will reimburse Intrexon for all research and development costs. Subject to certain expense allocations and other offsets provided in the ECC Agreement, the ECC Agreement also provides for equal sharing of the profits derived from the sale of the Products (Note 6). The liability was subsequently paid in October 2015.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Warrants

9 Months Ended

Sep. 30, 2015

Warrants

8. Warrants

The Company has issued both warrants that are accounted for as liabilities and warrants that are accounted for as equity instruments.

The Company follows accounting standards that provide guidance in assessing whether an equity-issued financial instrument is indexed to an entity’s own stock for purposes of determining whether a financial instrument should be treated as a derivative and classified as a liability. Accounting standards require that liability classified warrants be recorded at their fair value at each financial reporting period and the resulting gain or loss be recorded as other income (expense) in the statement of operations. Fair value is measured using the Binomial/Monte Carlo valuation model.

There were no warrants outstanding at September 30, 2015 or December 31, 2014.

Liability-Classified Warrants

In connection with the December 2009 public offering, the Company issued warrants to purchase an aggregate of 8,206,520 shares of common stock, including the investor warrants and 464,520 warrants issued to the underwriters. The warrants had a 5 year term and expired in December 2014. Subject to certain exceptions, these warrants provided anti-dilution protection in the event the Company should subsequently issue common stock or common stock equivalents at a price less than the exercise price of the warrants then in effect.

The Company assessed whether the Warrants require accounting as derivatives. The Company determined that these warrants were not indexed to the Company’s own stock in accordance with Accounting Standards Codification Topic 815, Derivatives and Hedging. As such, the Company has concluded these warrants did not meet the scope exception for determining whether the instruments require accounting as derivatives and were classified as liabilities.

The Company used the Binomial/Monte Carlo valuation model to estimate the value of the liability-classified warrants. The following assumptions were used in the Binomial/Monte Carlo valuation model at September 30, 2014:


		2014
Risk-free interest rate		0.02%
Expected life in years		0.19
Expected volatility		65%
Expected dividend yield		0
Steps per year		125

The change in the fair value of the warrant liability resulted in a gain of $5.8 million and $11.5 million for the three and nine months ended September 30, 2014, respectively. The change in the fair value of the warrant liability was charged to other income (expense) in the statement of operations.

During the nine months ended September 30, 2014, there were 2,292,362 warrants exercised for 1,991,409 shares of common stock.

Common Stock

9 Months Ended

Sep. 30, 2015

Common Stock

9. Common Stock

On February 3, 2015, the Company entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the several underwriters named therein, relating to the issuance and sale of 10,000,000 shares of the Company’s common stock. The price to the public in the offering was $8.75 per share, and the underwriters agreed to purchase the shares from the Company pursuant to the underwriting agreement at a purchase price of $8.225 per share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,500,000 shares of common stock at a purchase price of $8.225 per share. The offering was made pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-201826) previously filed with the SEC, and a prospectus supplement thereunder. The underwriters purchased the 10,000,000 shares and the additional 1,500,000 shares on February 9 and 17, 2015, respectively. The net proceeds from the offering were approximately $94.3 million after deducting underwriting discounts and estimated offering expenses payable by the Company.

On January 13, 2015, the Company, together with Intrexon, entered into the MD Anderson License. Pursuant to the terms of the MD Anderson License, MD Anderson received consideration of 11,722,163 shares of the Company’s common stock (Note 6).

Stock-Based Compensation

9 Months Ended

Sep. 30, 2015

Stock-Based Compensation

10. Stock-Based Compensation

The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:


	For the three months ended September 30,				For the nine months ended September 30,
(in thousands)	2015		2014		2015		2014
Research and development	$	264	$	340	$	874	$	1,126
General and administrative		1,213		808		5,180		2,457

Stock-based employee compensation expense	$	1,477	$	1,148	$	6,054	$	3,583

The Company granted an aggregate of 203,000 and 254,800 stock options during the three and nine months ended September 30, 2015 with a weighted-average grant date fair value of $8.49 and $8.10 per share, respectively. The Company granted an aggregate of 10,000 and 114,300 stock options during the three and nine months ended September 30, 2014 with a weighted-average grant date fair value of $2.29 and $3.15 per share, respectively.

On March 31, 2014, the Company extended the contractual life of 71,167 fully vested stock options held by one employee for an additional 9 months.

On March 31, 2014, the Company extended the contractual life of 33,333 fully vested stock options and 66,667 unvested stock options held by one employee for an additional 6 months.

On September 8, 2014, the Company extended the contractual life of 82,834 fully vested stock options and 23,333 unvested stock options held by one employee for an additional 3 months.

On September 15, 2014, the Company extended the contractual life of 39,167 fully vested stock options and 113,333 unvested stock options held by one employee for an additional 27 months.

On June 17, 2015, the Company extended the contractual life of 157,500 fully vested stock options held by a director for an additional 48 months.

The additional expense for the above modifications totaled $325 thousand for the year ended December 31, 2014 and $201 thousand for the nine months ended September 30, 2015.

For the three months ended September 30, 2015 and 2014, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:


	For the three months ended September 30,
	2015	2014
Risk-free interest rate	1.66 - 1.93%	2.03%
Expected life in years	6	6
Expected volatility	80.01 - 81.17%	92.36%
Expected dividend yield	0	0

Stock option activity under the Company’s stock option plan for the nine months ended September 30, 2015 is as follows:


(in thousands, except share and per share data)	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2014		6,505,663		$	4.07

Granted		254,800			11.61
Exercised		(2,938,161	)		3.96
Cancelled		(167,167	)		4.13

Outstanding, September 30, 2015		3,655,135		$	4.69		7.09	$	16,481

Vested and unvested expected to vest at September 30, 2015		3,579,108		$	4.09		5.59	$	16,139

Options exercisable, September 30, 2015		1,886,001		$	4.09		5.59	$	9,277

Options exercisable, December 31, 2014		3,781,162		$	4.10		5.80	$	4,130

Options available for future grant		3,441,950

At September 30, 2015, total unrecognized compensation costs related to unvested stock options outstanding amounted to $5.1 million. The cost is expected to be recognized over a weighted-average period of 1.59 years.

During the three and nine months ended September 30, 2015, the Company issued 4,186 and 1,054,186 shares of restricted stock to employees and directors. The employee grants vest ratably in annual installments over three years, commencing on the first anniversary of the grant date and the director grant vests in total on December 31, 2015. No shares of restricted stock were issued during the three or nine months ended September 30, 2014.

A summary of the status of unvested restricted stock for the nine months ended September 30, 2015 is as follows:


	Number of Shares			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2014		144,508		$	4.70
Granted		1,054,186			9.36
Vested		(70,991	)		4.62
Cancelled		—			—

Non-vested, September 30, 2015		1,127,703		$	9.06

At September 30, 2015, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $8.6 million. The cost is expected to be recognized over a weighted-average period of 1.83 years.

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2015

Assets and Liabilities Measured at Fair Value on Recurring Basis

Assets and liabilities measured at fair value on a recurring basis as of September 30, 2015 and December 31, 2014 were as follows:


($ in thousands)			Fair Value Measurements at Reporting Date Using
Description	Balance as of September 30, 2015		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	160,930	$	160,930	$	—	$	—


($ in thousands)			Fair Value Measurements at Reporting Date Using
Description	Balance as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	37,290	$	37,290	$	—	$	—

Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2015

Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share

The Company’s potential dilutive shares, which include outstanding common stock options, unvested restricted stock and warrants, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potential shares of common stock at September 30, 2015 and 2014 consisted of the following:


	September 30,
	2015		2014
Stock options		3,655,135		5,792,428
Unvested restricted common stock		1,127,703		283,433
Warrants		—		8,235,076

		4,782,838		14,310,937

Warrants (Tables)

9 Months Ended

Sep. 30, 2015

Assumptions Used in Binomial and Monte Carlo Valuation Model

The following assumptions were used in the Binomial/Monte Carlo valuation model at September 30, 2014:


		2014
Risk-free interest rate		0.02%
Expected life in years		0.19
Expected volatility		65%
Expected dividend yield		0
Steps per year		125

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2015

Stock-Based Compensation Expense on All Employee and Non-Employee Awards

The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:


	For the three months ended September 30,				For the nine months ended September 30,
(in thousands)	2015		2014		2015		2014
Research and development	$	264	$	340	$	874	$	1,126
General and administrative		1,213		808		5,180		2,457

Stock-based employee compensation expense	$	1,477	$	1,148	$	6,054	$	3,583

Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model

For the three months ended September 30, 2015 and 2014, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:


	For the three months ended September 30,
	2015	2014
Risk-free interest rate	1.66 - 1.93%	2.03%
Expected life in years	6	6
Expected volatility	80.01 - 81.17%	92.36%
Expected dividend yield	0	0

Stock Option Activity Under Stock Option Plan

Stock option activity under the Company’s stock option plan for the nine months ended September 30, 2015 is as follows:


(in thousands, except share and per share data)	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2014		6,505,663		$	4.07

Granted		254,800			11.61
Exercised		(2,938,161	)		3.96
Cancelled		(167,167	)		4.13

Outstanding, September 30, 2015		3,655,135		$	4.69		7.09	$	16,481

Vested and unvested expected to vest at September 30, 2015		3,579,108		$	4.09		5.59	$	16,139

Options exercisable, September 30, 2015		1,886,001		$	4.09		5.59	$	9,277

Options exercisable, December 31, 2014		3,781,162		$	4.10		5.80	$	4,130

Options available for future grant		3,441,950

Summary of Unvested Restricted Stock

A summary of the status of unvested restricted stock for the nine months ended September 30, 2015 is as follows:


	Number of Shares			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2014		144,508		$	4.70
Granted		1,054,186			9.36
Vested		(70,991	)		4.62
Cancelled		—			—

Non-vested, September 30, 2015		1,127,703		$	9.06

Business - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Nature Of Operations [Line Items]
Accumulated deficit	$ (483,224)	$ (372,612)

Financings - Additional Information (Detail) - J.P. Morgan Securities Inc. - USD ($) $ / shares in Units, $ in Millions	Feb. 17, 2015	Feb. 03, 2015
Class of Stock [Line Items]
Stock issued during period	1,500,000	10,000,000
Issuance & sale of common stock in public offering price per share		$ 8.75
Option granted, exercisable period		30 days
Sale of stock price per share		$ 8.225
Net proceeds from issuance of common stock	$ 94.3

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 160,930	$ 37,290
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 160,930	$ 37,290

Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	4,782,838	14,310,937
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	3,655,135	5,792,428
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,127,703	283,433
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		8,235,076

Commitments and Contingencies - Additional Information (Detail)											1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Oct. 13, 2015 USD ($)	Sep. 28, 2015 USD ($)	May 22, 2015 USD ($)	Mar. 31, 2015 USD ($)	Jan. 13, 2015 USD ($) shares	Jan. 09, 2015 USD ($) shares	Aug. 30, 2013 ft²	Mar. 07, 2011 USD ($)	Jan. 06, 2011	Aug. 24, 2004 Patent	Jul. 31, 2015 USD ($)	Sep. 30, 2015 USD ($) ft² $ / shares shares	Mar. 31, 2015 USD ($)	Sep. 30, 2014 USD ($) shares	Sep. 30, 2015 USD ($) ft² Agreement $ / shares shares	Sep. 30, 2014 USD ($) shares	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($) ft²	Dec. 31, 2011 USD ($) ft²	May 31, 2015 USD ($)	Oct. 15, 2014 USD ($)	Nov. 02, 2012 USD ($)	Jun. 30, 2012 USD ($) ft²	Jan. 31, 2012 ft²
Commitments and Contingencies Disclosure [Line Items]
Loss on disposal of fixed assets															$ 1,000
Total rent Expense															581,000	$ 445,000
Deferred rent - current portion												$ 402,000			402,000		$ 280,000
Deferred rent-non-current portion												379,000			379,000		570,000
Deferred rent liability net												781,000			781,000		850,000
Research and Development Expense												16,970,000		$ 9,733,000	98,643,000	24,621,000
Research and development arrangement Terms					Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15 million and no greater than $20 million per year.
Research and Development Service Agreement Quarterly Payment															7,500,000
Offset costs in research and development expense															372,000
Deferred revenue - current portion												6,933,000			6,933,000		1,360,000
Deferred Revenue, long term												49,514,000			49,514,000
Research contract revenue												1,869,000		633,000	2,413,000	1,033,000
Prepaid Expenses and Other Current Assets
Commitments and Contingencies Disclosure [Line Items]
Pre paid research and development expenses												$ 7,100,000			$ 7,100,000
Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Research and Development Service Agreement Quarterly Payment	$ 3,800,000
DEKK Tec Inc
Commitments and Contingencies Disclosure [Line Items]
Milestone maximum payment																						$ 4,000,000
Option to purchase common stock \| shares															27,616
Sale of stock price per share \| $ / shares												$ 0.02			$ 0.02
Outstanding options to purchase common stock \| shares												13,808			13,808
Southern Research Institute
Commitments and Contingencies Disclosure [Line Items]
Milestone maximum payment																	775,000
Royalty payment																	25,000	$ 25,000	$ 25,000
The University of Texas MD Anderson Cancer Center and The Texas A & M University System
Commitments and Contingencies Disclosure [Line Items]
Milestone maximum payment														$ 4,500,000		$ 4,500,000
Option to purchase common stock \| shares															50,222
Number of products \| Patent										2
The University of Texas MD Anderson Cancer Center and The Texas A & M University System \| Upon enrollment of the first patient in a multi-center pivotal clinical trial
Commitments and Contingencies Disclosure [Line Items]
Shares expected to vest \| shares														12,556		12,556
Solasia
Commitments and Contingencies Disclosure [Line Items]
Upfront payment received								$ 5,000,000
Deferred revenue - current portion												$ 544,000			$ 544,000
Research contract revenue												272,000		$ 633,000	816,000	$ 1,000,000
Estimated upfront payment for research and development funding earning period																75 months
Solasia \| Development-based milestones
Commitments and Contingencies Disclosure [Line Items]
Expected Additional milestone payments to be received															32,500,000
Solasia \| Sales-based milestones
Commitments and Contingencies Disclosure [Line Items]
Expected Additional milestone payments to be received															53,500,000
Baxter Healthcare Corporation \| Upon the successful U.S. IND application for indibulin
Commitments and Contingencies Disclosure [Line Items]
Installment payments															$ 0		250,000	250,000
Novella Clinical, Inc.
Commitments and Contingencies Disclosure [Line Items]
Milestone maximum payment																							$ 790,000
Number of amendments signed \| Agreement															2
Novella Clinical, Inc. \| Upon three clinical milestones
Commitments and Contingencies Disclosure [Line Items]
Installment payments													$ 10,000				236,000
Minimum
Commitments and Contingencies Disclosure [Line Items]
Research and Development Expense					$ 15,000,000
Maximum
Commitments and Contingencies Disclosure [Line Items]
Research and Development Expense					20,000,000
License Agreement
Commitments and Contingencies Disclosure [Line Items]
Research and Development Expense															$ 67,300,000
Issuance of common stock in licensing agreement, shares \| shares															11,722,163
Merck License
Commitments and Contingencies Disclosure [Line Items]
Agreement termination, notice period															90 days
Payments for development and commercial milestones per Product															$ 413,000,000
Milestone payments, percentage															50.00%
Agreement commencement date															2015-05
Deferred revenue, revenue recognized												1,600,000			$ 1,600,000
Deferred revenue, upfront payment												55,900,000			$ 55,900,000						$ 57,500,000
Intrexon Corporation
Commitments and Contingencies Disclosure [Line Items]
Contract termination description															The Company's obligation to pay 50% of net profits or revenue described above with respect to these "retained" products will survive termination of the Channel Agreement.
Licensing fee		$ 10,000,000									$ 115,000,000
Milestone payment receivable															$ 5,000,000
Milestone payment receivable period															2 years
Upfront payment received											$ 57,500,000
Percentage of upfront fee Payable											50.00%
Milestone maximum payment												50,000,000			$ 50,000,000
Intrexon Corporation \| Quarterly Payment
Commitments and Contingencies Disclosure [Line Items]
Percent of company net profit									50.00%
Percentage of revenue agreed to pay which is obtained from sublicensor									50.00%
Intrexon Corporation \| Letter Agreement
Commitments and Contingencies Disclosure [Line Items]
Cash consideration for license agreement						$ 7,500,000
Intrexon Corporation \| License Agreement
Commitments and Contingencies Disclosure [Line Items]
Cash consideration for license agreement					$ 50,000,000
Intrexon Corporation \| GVHDA Arrangement
Commitments and Contingencies Disclosure [Line Items]
Percent of company net profit															50.00%
Contract termination description															The Company's obligation to pay 50% of net profits or revenue with respect to these "retained" products will survive termination of the GvHD Agreement.
Licensing fee		$ 10,000,000
Agreement termination period		24 months
Agreement termination, notice period		90 days
Research and Development Expense															$ 10,000,000
Ziopharm \| Letter Agreement
Commitments and Contingencies Disclosure [Line Items]
Common stock issued for cash \| shares						1,597,602
Cash consideration for license agreement						$ 7,500,000
Ziopharm \| License Agreement
Commitments and Contingencies Disclosure [Line Items]
Common stock issued for cash \| shares					10,124,561
Cash consideration for license agreement					$ 50,000,000
New York, NY
Commitments and Contingencies Disclosure [Line Items]
Office space under operating lease \| ft²																			7,259	6,251
Letter of credit												$ 388,000			$ 388,000				$ 388,000	$ 388,000
Additional office space under operating lease \| ft²																									1,008
Operating lease expiration month and year																			2018-10
Loss on sublease																		729,000
Remaining contractual obligation																		2,300,000
Sublease revenue from subtenant																		1,600,000
Loss on disposal of fixed assets																		(392,000)
Boston, MA
Commitments and Contingencies Disclosure [Line Items]
Office space under operating lease \| ft²												21,184			21,184
Operating lease expiration month and year			2016-08																	2016-08
Loss on sublease																		42,000
Remaining contractual obligation																		367,000
Sublease revenue from subtenant			$ 105,000															$ 325,000
Security deposits			$ 17,000									$ 127,000			$ 127,000
Area under sublease agreement \| ft²							5,249
Security deposit from subtenant																	$ 20,000
Boston, MA \| The first floor
Commitments and Contingencies Disclosure [Line Items]
Loss on sublease				$ 167,000
Operating lease space \| ft²																				5,249
Boston, MA \| The second floor
Commitments and Contingencies Disclosure [Line Items]
Office space under operating lease \| ft²																								4,113
Operating lease space \| ft²																				8,538
Boston, MA \| The third floor
Commitments and Contingencies Disclosure [Line Items]
Operating lease space \| ft²																				6,959
Boston, MA \| The four floor
Commitments and Contingencies Disclosure [Line Items]
Office space under operating lease \| ft²																								9,800
Security deposits																								$ 41,000

Related Party Transactions - Additional Information (Detail) - USD ($)							1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 28, 2015	Jun. 29, 2015	Mar. 27, 2015	Feb. 02, 2015	Jan. 13, 2015	Jan. 06, 2011	Jul. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Related Party Transaction [Line Items]
Commitment to purchase common stock										$ 34,000
Research and Development Expense								$ 16,970,000	$ 9,733,000	98,643,000	$ 24,621,000
Stock buy back										34,000
Minimum
Related Party Transaction [Line Items]
Research and Development Expense					$ 15,000,000
License Agreement
Related Party Transaction [Line Items]
Research and Development Expense										$ 67,300,000
Issuance of common stock in licensing agreement (in shares)										11,722,163
Md Anderson Cancer Center \| Minimum
Related Party Transaction [Line Items]
Ownership percentage								5.00%		5.00%
Intrexon Corporation
Related Party Transaction [Line Items]
Commitment to purchase common stock			$ 43,500,000			$ 50,000,000
Percentage of commitment for payments from receipts of upfronts, milestones and royalties			50.00%
Stock issued during period				1,440,000
Stock buy back (Shares)		3,711
Stock buy back		$ 34,000
Share buy back discount on closing price		5.00%
Amounts paid for services incurred										$ 11,700,000	9,100,000
Amount due to related party, current								$ 5,700,000	$ 2,300,000	$ 5,700,000	$ 2,300,000
Licensing fee	$ 10,000,000						$ 115,000,000

Warrants - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2009
Class of Warrant or Right [Line Items]
Warrants to purchase an aggregate of shares of common stock				8,206,520
Warrant term				5 years
Warrants expiration date		2014-12
Change in fair value of warrants	$ 5,847		$ 11,529
Warrants exercised			2,292,362
Conversion of Warrants to Common Stock			1,991,409
J. P. Morgan Securities LLC
Class of Warrant or Right [Line Items]
Warrants issued				464,520

Assumptions Used In Binomial Valuation Model and Black-Scholes Valuation Model (Detail) - Black Scholes Option Pricing Model - Warrants	9 Months Ended
	Sep. 30, 2014 Step
Class of Warrant or Right [Line Items]
Risk-free interest rate	0.02%
Expected life in years	2 months 9 days
Expected volatility	65.00%
Expected dividend yield	0.00%
Steps per year	125

Common Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions			9 Months Ended
	Feb. 17, 2015	Feb. 03, 2015	Sep. 30, 2015
License Agreement
Class of Stock [Line Items]
Issuance of common stock in licensing agreement (in shares)			11,722,163
J.P. Morgan Securities Inc.
Class of Stock [Line Items]
Issuance of common stock in public offering (in shares)	1,500,000	10,000,000
Issuance & sale of common stock in public offering price per share		$ 8.75
Option granted, exercisable period		30 days
Sale of stock price per share		$ 8.225
Net proceeds from issuance of common stock	$ 94.3

Stock-Based Compensation Expense Included in Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 1,477	$ 1,148	$ 6,054	$ 3,583
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	264	340	874	1,126
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 1,213	$ 808	$ 5,180	$ 2,457

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 17, 2015	Sep. 15, 2014	Sep. 08, 2014	Mar. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted					203,000	10,000	254,800	114,300
Weighted-average grant date fair value					$ 8.49	$ 2.29	$ 8.10	$ 3.15
Additional expense for modifications							$ 201		$ 325
Unrecognized compensation costs, employee stock options					$ 5,100		$ 5,100
Expected recognition period							1 year 7 months 2 days
Employee Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vested				33,333
Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vested	157,500
Shares vesting period	48 months
Vested options held by 1 employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vested		39,167	82,834	71,167
Shares vesting period				9 months
Unvested options held by 1 employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vesting period		27 months	3 months	6 months
Shares unvested		113,333	23,333	66,667
Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected recognition period							1 year 9 months 29 days
Unrecognized compensation costs					$ 8,600		$ 8,600
Restricted Stock \| Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share vesting date							Dec. 31, 2015
Restricted Stock \| Employees and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vesting period					3 years
Shares issued					4,186	0	1,054,186	0

Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		2.03%
Expected life in years	6 years	6 years
Expected volatility		92.36%
Expected dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.66%
Expected volatility	80.01%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.93%
Expected volatility	81.17%

Stock Option Activity Under Stock Option Plan (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Number of Shares
Beginning Balance			6,505,663
Granted	203,000	10,000	254,800	114,300
Exercised			(2,938,161)
Cancelled			(167,167)
Ending Balance	3,655,135		3,655,135		6,505,663
Vested and unvested expected to vest at end of period	3,579,108		3,579,108
Options exercisable, at end of period	1,886,001		1,886,001		3,781,162
Options available for future grant	3,441,950		3,441,950
Weighted Average Exercise Price
Beginning Balance			$ 4.07
Granted			11.61
Exercised			3.96
Cancelled			4.13
Ending Balance	$ 4.69		4.69		$ 4.07
Vested and unvested expected to vest at end of period	4.09		4.09
Options exercisable, at end of period	$ 4.09		$ 4.09		$ 4.10
Weighted Average Contractual Term (Years)
Outstanding, at end of period			7 years 1 month 2 days
Vested and unvested expected to vest at end of period			5 years 7 months 2 days
Options exercisable, at end of period			5 years 7 months 2 days		5 years 9 months 18 days
Aggregate Intrinsic Value
Outstanding, at end of period	$ 16,481		$ 16,481
Vested and unvested expected to vest at end of period	16,139		16,139
Options exercisable, at end of period	$ 9,277		$ 9,277		$ 4,130

Summary of Unvested Restricted Stock (Detail) - Unvested Restricted Common Stock	9 Months Ended
	Sep. 30, 2015 $ / shares shares
Number of Shares
Beginning Balance \| shares	144,508
Granted \| shares	1,054,186
Vested \| shares	(70,991)
Cancelled \| shares	0
Ending Balance \| shares	1,127,703
Weighted Average Grant Date Fair Value
Beginning Balance \| $ / shares	$ 4.70
Granted \| $ / shares	9.36
Vested \| $ / shares	4.62
Cancelled \| $ / shares	0
Ending Balance \| $ / shares	$ 9.06